Code covers all interactions with healthcare professionals, medical institutions, and patient organizations Code provides effective framework for ethical business practices Company and association members of IFPMA adopt updated standards Today the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) announced that its expanded Code of Practice is in effect around the world. Governing how companies...
Read moreFour major pharmaceutical associations issue joint policy statement to crack down on counterfeits from illicit Internet pharmacies and other sources Statement comes as the U.S. launches Center for Safe Internet Pharmacies (CSIP) initiative The global pharmaceutical industry unveiled recommendations today to tackle the growing public health threat of counterfeit or fake medicines. The industry’s call...
Read moreThe International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the global Biotechnology Industry Organization (BIO) and the World Anti-Doping Agency (WADA) today announced the launch of the 2 FIELDS 1 GOAL: Protecting the Integrity of Science and Sport campaign, that aims to achieve the goals of the Joint Declaration on Cooperation in the Fight against...
Read moreMasafumi Nogimori and Stefan Oschmann become IFPMA Acting President and Acting Vice President respectively The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) announced changes to its leadership team today. Mr. Masafumi Nogimori of Astellas Pharma Inc. becomes IFPMA Acting President while Dr. Stefan Oschmann of Merck KGaA becomes IFPMA Acting Vice President. These announcements...
Read moreInternational Federation of Pharmaceutical Manufacturers & Associations contributes to discussions during World Health Assembly Key issues include coordination of research and development for diseases of the developing world, vaccines, fake medicines, and neglected tropical diseases As one of the 189 nongovernmental organizations (NGOs) in official relations with the World Health Organization (WHO), the International Federation...
Read moreIFPMA Statement, WHA 65, Item 13.14, Consultative expert working group on research and development: financing and coordination Delivered by Mario Ottiglio, Associate Director, Public Affairs & Global Health Policy Thank you on behalf of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), for the opportunity to provide our perspective on this topic. We represent...
Read moreIFPMA Statement, WHA 65, Item 13.11, Elimination of Schistomiasis Delivered by Mr Mario Ottiglio, Associate Director, Public Affairs and Global Health Policy Thank you for the opportunity to input on the important discussions regarding the elimination of schistosomiasis. The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents leading research-based pharmaceutical companies as well as...
Read moreIFPMA Statement under WHA 65 agenda item 13.13 on Substandard / spurious / falsely-labelled / falsified / counterfeit medical products Delivered by Mr Mario Ottiglio, Associate Director, Public Affairs and Global Health Policy Thank you on behalf of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), for the opportunity to provide our perspective on...
Read moreIFPMA Statement under WHA 65 agenda item 13.12 on Draft global vaccine action plan Thank you on behalf of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), for the opportunity to provide our perspective on issues related to global immunization. IFPMA represents the global R&D pharmaceutical industry, whose primary contribution to global health is...
Read more10 May 2012, Geneva – A new study was released today reviewing initiatives to encourage research and development (R&D) for diseases such as HIV, tuberculosis, malaria and neglected tropical diseases. The report, titled “Assembling the pharmaceutical R&D puzzle for needs in the developing world,” introduces a blueprint based on six enabling factors that comprise: identification...
Read morePresentation by Dr. Markus Boehringer, Head of External Innovation & Alliances CVM Diseases, F. Hoffmann-La Roche. Geneva Pharma Forum on Biopharmaceutical Innovation. 17 April 2012 at WIPO
Read more